Ракът на маточната шийка се счита за едно от заболяванията с най-висока смъртност сред жените и с ограничени възможности за лечение. Съобщава се, че вдишването на водород (H 2 ) има различни тумор-супресивни ефекти, но точният механизъм остава неясен. В настоящото изследване, HeLa ракови клетки на маточната шийка и HaCaT кератиноцити, третирани с H 2 , и HeLa ксенотрансплантат миши модел, подложен на H 2са установени вдишване.
За откриване на клетъчна апоптоза и пролиферация бяха използвани TUNEL, комплект за преброяване на клетки-8 и Ki67. Оксидативният стрес се определя според нивата на реактивни кислородни видове, малонов диалдехид и супероксид дисмутаза. Растежът на тумора се записва на всеки 3 дни, а изрязаните тумори се оцветяват с хематоксилин и еозин.
Високопроизводително секвениране на РНК и последващ анализ на обогатяване на генна онтология (GO) бяха извършени в HeLa-третирани и нетретирани HeLa клетки. Експресията на индуцируем от хипоксия фактор (HIF)-1α и NF-κB p65 беше потвърдена чрез Western blotting, имунохистохимия и количествена PCR с обратна транскрипция. Резултатите разкриват повишена скорост на апоптоза и намалена клетъчна пролиферация и оксидативен стрес в H 2-третирани HeLa клетки, но не и в HaCaT клетки.
По същия начин, намален туморен растеж и клетъчна пролиферация, както и повишена клетъчна апоптоза се наблюдават при H2-третирани HeLa тумори. РНК секвенирането и GO анализът предполагат, че понижените нива на HIF1A (HIF-1α mRNA) и RelA (NF-κB p65) и намалената сигнализация на NF-κB са свързани с антитуморния ефект на H 2 .
Накрая, намалена експресия на HIF-1α и NF-κB p65 както на транскрипционните, така и на транслационните нива се наблюдава в H 2 – третирани HeLa клетки и в тумори, получени от HeLa.
В заключение, настоящото проучване разкрива нов механизъм на водорода срещу рак на маточната шийка, който може да служи като потенциална терапевтична цел в клиничната практика.
1
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.
2
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.
3
Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L and Mangioni C: Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 350:535–540. 1997.
4
Neeman E and Ben-Eliyahu S: Surgery and stress promote cancer metastasis: New outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 30 (Suppl 1):S32–S40. 2013.
5
Hodson R: Precision medicine. Nature. 537:S492016.
6
Tannock IF and Hickman JA: Limits to personalized cancer medicine. N Engl J Med. 375:1289–1294. 2016.
7
Sano M, Suzuki M, Homma K, Hayashida K, Tamura T, Matsuoka T, Katsumata Y, Onuki S and Sasaki J: Promising novel therapy with hydrogen gas for emergency and critical care medicine. Acute Med Surg. 5:113–118. 2017.
8
Ge L, Yang M, Yang NN, Yin XX and Song WG: Molecular hydrogen: A preventive and therapeutic medical gas for various diseases. Oncotarget. 8:102653–102673. 2017.
9
Ohta S: Molecular hydrogen as a preventive and therapeutic medical gas: Initiation, development and potential of hydrogen medicine. Pharmacol Ther. 144:1–11. 2014.
10
Tamura T, Suzuki M, Hayashida K, Kobayashi Y, Yoshizawa J, Shibusawa T, Sano M, Hori S and Sasaki J: Hydrogen gas inhalation alleviates oxidative stress in patients with post-cardiac arrest syndrome. J Clin Biochem Nutr. 67:214–221. 2020.
11
Chen L, Chao Y, Cheng P, Li N, Zheng H and Yang Y: UPLC-QTOF/MS-based metabolomics reveals the protective mechanism of hydrogen on mice with ischemic stroke. Neurochem Res. 44:1950–1963. 2019.
12
Yang Y, Liu PY, Bao W, Chen SJ, Wu FS and Zhu PY: Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway. BMC Cancer. 20:282020.
13
Wang D, Wang L, Zhang Y, Zhao Y and Chen G: Hydrogen gas inhibits lung cancer progression through targeting SMC3. Biomed Pharmacother. 104:788–797. 2018.
14
Harguindey S, Alfarouk K, Orozco JP, Hardonniere K, Stanciu D, Fais S and Devesa J: A new and integral approach to the etiopathogenesis and treatment of breast cancer based upon its hydrogen ion dynamics. Int J Mol Sci. 21:11102020.
15
Chen JB, Kong XF, Lv YY, Qin SC, Sun XJ, Mu F, Lu TY and Xu KC: ‘Real world survey’ of hydrogen-controlled cancer: A follow-up report of 82 advanced cancer patients. Med Gas Res. 9:115–121. 2019.
16
Andrews KR, Good JM, Miller MR, Luikart G and Hohenlohe PA: Harnessing the power of RADseq for ecological and evolutionary genomics. Nat Rev Genet. 17:81–92. 2016.
17
Masters JR: HeLa cells 50 years on: The good, the bad and the ugly. Nat Rev Cancer. 2:315–319. 2002.
18
Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J, Pääbo S and Mann M: Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol. 7:5482011.
19
Tavakolian S, Goudarzi H, Eslami G and Faghihloo E: Transcriptional regulation of epithelial to mesenchymal transition related genes by lipopolysaccharide in human cervical cancer cell line HeLa. Asian Pac J Cancer Prev. 20:2455–2461. 2019.
20
Johrens K, Lazzerini L, Barinoff J, Sehouli J and Cichon G: Mesothelin as a target for cervical cancer therapy. Arch Gynecol Obstet. 299:211–216. 2019.
21
Lin Y, Ohkawara B, Ito M, Misawa N, Miyamoto K, Takegami Y, Masuda A, Toyokuni S and Ohno K: Molecular hydrogen suppresses activated Wnt/β-catenin signaling. Sci Rep. 6:319862016.
22
Kamalipooya S, Abdolmaleki P, Salemi Z, Javani Jouni F, Zafari J and Soleimani H: Simultaneous application of cisplatin and static magnetic field enhances oxidative stress in HeLa cell line. In Vitro Cell Dev Biol Anim. 53:783–790. 2017.
23
Metsalu T and Vilo J: ClustVis: A web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 43:W566–W570. 2015.
24
Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009.
25
Rao X, Huang X, Zhou Z and Lin X: An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
26
Finkel T and Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature. 408:239–247. 2000.
27
Costa V and Moradas-Ferreira P: Oxidative stress and signal transduction in Saccharomyces cerevisiae: Insights into ageing, apoptosis and diseases. Mol Aspects Med. 22:217–246. 2001.
28
DiDonato JA, Mercurio F and Karin M: NF-κB and the link between inflammation and cancer. Immunol Rev. 246:379–400. 2012.
29
Trottier H and Burchell AN: Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 12:291–307. 2009.
30
McBride AA: Oncogenic human papillomaviruses. Philos Trans R Soc Lond B Biol Sci. 372:201602732017.
31
Viarisio D, Gissmann L and Tommasino M: Human papillomaviruses and carcinogenesis: Well-established and novel models. Curr Opin Virol. 26:56–62. 2017.
32
St Laurent J, Luckett R and Feldman S: HPV vaccination and the effects on rates of HPV-related cancers. Curr Probl Cancer. 42:493–506. 2018.
33
Tornesello ML, Faraonio R, Buonaguro L, Annunziata C, Starita N, Cerasuolo A, Pezzuto F, Tornesello AL and Buonaguro FM: The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer. Front Oncol. 10:1502020.
34
Casarotto M, Fanetti G, Guerrieri R, Palazzari E, Lupato V, Steffan A, Polesel J, Boscolo-Rizzo P and Fratta E: Beyond microRNAs: Emerging role of other non-coding RNAs in HPV-driven cancers. Cancers (Basel). 12:12462020.
35
Wen X, Liu S, Sheng J and Cui M: Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer. PeerJ. 8:e92342020.
36
Vojtechova Z and Tachezy R: The role of miRNAs in virus-mediated oncogenesis. Int J Mol Sci. 19:12172018.
37
Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66:7390–7394. 2006.
38
Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR and Israel MA: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67:2456–2468. 2007.
39
Taniguchi K and Karin M: NF-κB, inflammation, immunity and cancer: Coming of age. Nat Rev Immunol. 18:309–324. 2018.
40
Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
41
Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin AS Jr: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 19:5785–5799. 1999.
42
La Rosa FA, Pierce JW and Sonenshein GE: Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol. 14:1039–1044. 1994.
43
Perkins ND: Achieving transcriptional specificity with NF-kappa B. Int J Biochem Cell Biol. 29:1433–1448. 1997.
44
Vaupel P and Mayer A: Hypoxia in tumors: Pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv Exp Med Biol. 812:19–24. 2014.
45
Zhou J, Schmid T, Schnitzer S and Brune B: Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006.
46
Semenza GL: Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 9:47–71. 2014.
47
Wenger RH, Stiehl DP and Camenisch G: Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005:re122015.PubMed/NCBI
48
Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
49
Seeber LM, Horree N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH and van Diest PJ: The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol. 78:173–184. 2011.
50
Keith B, Johnson RS and Simon MC: HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 12:9–22. 2011.
51
Scholz CC and Taylor CT: Targeting the HIF pathway in inflammation and immunity. Curr Opin Pharmacol. 13:646–653. 2013.
52
Hervouet E, Cizkova A, Demont J, Vojtiskova A, Pecina P, Franssen-van Hal NL, Keijer J, Simonnet H, Ivanek R, Kmoch S, et al: HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis. 29:1528–1537. 2008.
53
Hao Y, Yan Z, Zhang A, Hu S, Wang N, Luo XG, Ma W, Zhang TC and He H: IL-6/STAT3 mediates the HPV18 E6/E7 stimulated upregulation of MALAT1 gene in cervical cancer HeLa cells. Virus Res. 281:1979072020.
